Latanoprostene Bunod Suppliers & Bulk Manufacturers
Available Forms: Eye Drops
Available Strengths: 0.024%
Reference Brands: Vyzulta (USA)
Category:
Opthalmology
Latanoprostene Bunod is available in Eye Drops
and strengths such as 0.024%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Latanoprostene Bunod is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Latanoprostene Bunod can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Latanoprostene bunod, marketed under the brand name Vyzulta, is an ophthalmic medication used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a prostaglandin F2α analog that undergoes enzymatic metabolism in the eye, producing latanoprost acid and nitric oxide, which work through complementary mechanisms to lower intraocular pressure.
Latanoprost acid increases aqueous humor outflow via the uveoscleral pathway, while nitric oxide relaxes the trabecular meshwork, enhancing conventional aqueous humor drainage. This dual action effectively reduces intraocular pressure, helping prevent optic nerve damage and vision loss associated with glaucoma.
Vyzulta is administered as an ophthalmic solution, typically once daily under the supervision of an ophthalmologist. Its targeted mechanism, combined with favorable safety and tolerability, makes it a valuable therapeutic option for patients requiring consistent intraocular pressure control. Latanoprostene bunod provides improved efficacy through dual outflow pathways, representing an advanced approach in the management of glaucoma and ocular hypertension.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing